PRALATREXATE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA- A SYSTEMATIC REVIEW AND META-ANALYSIS
Author(s)
Yang Y1, Hsu YE2, Chiu H3, Chen Y1, Hsieh C4, Lin W5
1National Taiwan University, Taipei, Taiwan, 2Taipei Medical University, Taipei, Taiwan, 3Chinese Medical University, Taichung, Taiwan, 4Oriental Institute of Technology, New Taipei City, Taiwan, 5Chang Jung Christian University, Tainan, Taiwan
OBJECTIVES: Pralatrexate, the first drug to gain US FDA approval for treatment of relapsed/refractory peripheral T-cell lymphomas (PTCL) in 2009, was aimed to treat PTCL-not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, and anaplastic large cell lymphoma patients. There was absence of consensus regarding standard therapeutic measures. Randomized controlled trials comparing different treatment approaches for PTCL are very limited due to its rarity and the heterogeneity of subtypes. METHODS: We attempt to collect clinical approved evidences for the efficacy and safety of pralatrexate as a salvage treatment for relapsed/refractory PTCL by systematic review. Searches based on According to National Comprehensive Cancer Network (NCCN) Guidelines and explicit inclusion criteria and exclusion criteria are set for literature searching in PubMed, Cochrane Library and Web of Science. We evaluate primary efficacy outcome (ORR and 95% CI), secondary efficacy outcomes (overall survival and progression-free survival duration) and safety outcomes. RESULTS: Twenty-four studies were initially identified for abstract screening. After further checking by two independent reviewers, 11 records eligible for full-text reviews. A total of 351 relapsed/refractory PTCL patients were investigated from 11 studies. The median age for those treated with pralatrexate were ranged from 45 to 61.5. Before ORRs were compared, we adjusted the severity of diseases due to heterogeneous distribution of PTCL subtypes. CONCLUSIONS: Our study results indicate that pralatrexate is the salvage treatment of choice for the heavily pretreated patients.
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PCN22
Topic
Clinical Outcomes, Epidemiology & Public Health
Topic Subcategory
Comparative Effectiveness or Efficacy, Relating Intermediate to Long-term Outcomes, Safety & Pharmacoepidemiology
Disease
Oncology